Autobio Diagnostics Co Ltd
SSE:603658
Intrinsic Value
Autobio Diagnostics Co., Ltd. engages in the research, development, manufacturing, integration, service, and distribution of in vitro diagnostic reagents and instruments. [ Read More ]
The intrinsic value of one
Autobio Diagnostics Co Ltd
stock under the Base Case scenario is
69.76
CNY.
Compared to the current market price of 56.35 CNY,
Autobio Diagnostics Co Ltd
is
Undervalued by 19%.
Autobio Diagnostics Co Ltd's market capitalization is 32.7B CNY.
Autobio Diagnostics Co Ltd stock price is 56.35 CNY.
Autobio Diagnostics Co Ltd stock price (56.35 CNY) is 19% less than its Intrinsic Value (69.76 CNY).
Autobio Diagnostics Co Ltd stock price (56.35 CNY) is 13% less than its DCF Value (64.93 CNY). Open DCF Valuation
Autobio Diagnostics Co Ltd stock price (56.35 CNY) is 24% less than its Relative Value (74.59 CNY). Open Relative Valuation
Autobio Diagnostics Co Ltd has upside potential of 14% compared to the average analyst price target.
Open Wall St Estimates
Autobio Diagnostics Co Ltd's Revenue has grown by 1% over the past 12 months.
Autobio Diagnostics Co Ltd has positive Net Debt. This means that the company has more debt (837m CNY) than cash and short-term investments (443m CNY).
Autobio Diagnostics Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 11%.
Autobio Diagnostics Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 17% to 15%.
Autobio Diagnostics Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 14% to 11%.
Autobio Diagnostics Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 15%.
Autobio Diagnostics Co Ltd has positive three-year average ROIC (Return on Invested Capital): 15%. The company is efficient at using invested capital to generate operating income.
Autobio Diagnostics Co Ltd's Revenue is forecast to grow at a rate of 15% per year over the next 3 years.
Autobio Diagnostics Co Ltd has positive three-year average ROE (Return on Equity): 17%. The company is efficient at transforming stockholders' equity into net income.
Autobio Diagnostics Co Ltd's Revenue has been growing by 16% per year for the last 3 years.
Autobio Diagnostics Co Ltd has positive Free Cash Flow for the last twelve months.
Autobio Diagnostics Co Ltd has positive Net Income for the last twelve months.
Autobio Diagnostics Co Ltd has positive Operating Income for the last twelve months.
Autobio Diagnostics Co Ltd has positive Gross Profit for the last twelve months.
Autobio Diagnostics Co Ltd's short-term assets (6B CNY) exceed its short-term liabilties (2B CNY).
Autobio Diagnostics Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.1.
Autobio Diagnostics Co Ltd's long-term assets (11B CNY) exceed its long-term liabilties (3B CNY).
Autobio Diagnostics Co Ltd's Altman Z-Score is very high and is equal to 7.29.
Valuation Backtest
Autobio Diagnostics Co Ltd
Run backtest to discover the historical profit from buying and selling
Autobio Diagnostics Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Autobio Diagnostics Co Ltd
Balance Sheet Decomposition
Autobio Diagnostics Co Ltd
| Current Assets | 6.4B |
| Cash & Short-Term Investments | 443.1m |
| Receivables | 1.2B |
| Other Current Assets | 4.7B |
| Non-Current Assets | 4.7B |
| Long-Term Investments | 116.9m |
| PP&E | 3.6B |
| Intangibles | 348.9m |
| Other Non-Current Assets | 593.8m |
| Current Liabilities | 2.3B |
| Accounts Payable | 266m |
| Accrued Liabilities | 103.1m |
| Short-Term Debt | 757.2m |
| Other Current Liabilities | 1.1B |
| Non-Current Liabilities | 581.2m |
| Long-Term Debt | 79.5m |
| Other Non-Current Liabilities | 501.6m |
Earnings Waterfall
Autobio Diagnostics Co Ltd
|
Revenue
|
4.4B
CNY
|
|
Cost of Revenue
|
-1.7B
CNY
|
|
Gross Profit
|
2.7B
CNY
|
|
Operating Expenses
|
-1.6B
CNY
|
|
Operating Income
|
1.2B
CNY
|
|
Other Expenses
|
8.7m
CNY
|
|
Net Income
|
1.2B
CNY
|
Free Cash Flow Analysis
Autobio Diagnostics Co Ltd
Profitability Score
Profitability Due Diligence
Autobio Diagnostics Co Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
Autobio Diagnostics Co Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Autobio Diagnostics Co Ltd's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Score
Autobio Diagnostics Co Ltd's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Autobio Diagnostics Co Ltd
According to Wall Street analysts, the average 1-year price target for
Autobio Diagnostics Co Ltd
is 64.51 CNY
with a low forecast of 55.95 CNY and a high forecast of 76.65 CNY.
Shareholder Return
Price
Autobio Diagnostics Co Ltd
| Average Annual Return | 15.18% |
| Standard Deviation of Annual Returns | 42.38% |
| Max Drawdown | -69% |
| Market Capitalization | 32.7B CNY |
| Shares Outstanding | 586 272 256 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Autobio Diagnostics Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Autobio Diagnostics Co., Ltd. engages in the research, development, manufacturing, integration, service, and distribution of in vitro diagnostic reagents and instruments. The company is headquartered in Zhengzhou, Henan and currently employs 5,031 full-time employees. The company went IPO on 2016-09-01. The firm's main products include gnostic products, microbiology detection products, and related devices. The immunodiagnostic products include microplate chemiluminescence diagnostic reagents, Enzyme-Linked immunosorbent assay diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. The microbiology detection products include training detection reagents, susceptibility detection reagents and rapid detection reagents. The device products include microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers. The firm distributes its products in domestic markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Autobio Diagnostics Co Ltd
stock under the Base Case scenario is
69.76
CNY.
Compared to the current market price of 56.35 CNY,
Autobio Diagnostics Co Ltd
is
Undervalued by 19%.
You don't have any saved screeners yet
